Related Experiment Video
Updated: Jun 12, 2026
A Rapid, Simple Workflow for Quantification of External Adult Drosophila Structures
Published on: November 8, 2024
Drosophila as a novel therapeutic discovery tool for thyroid cancer
1Department of Developmental and Regenerative Biology, Mount Sinai School of Medicine, New York, New York 10029, USA.
Background:
Multiple endocrine neoplasia type II (MEN2) is a rare but aggressive cancer for which no effective treatment currently exists. A Drosophila model was developed to identify novel genetic modifier loci of oncogenic RET, as well as to provide a whole animal system to rapidly identify compounds that suppressed RET-dependent MEN2. ZD6474 (Vandetanib), currently in phase III trials, suppressed tumorigenesis in MEN2 model flies, demonstrating for the first time the effectiveness of a Drosophila-based whole animal model for identifying therapeutically useful compounds.
Summary:
Clinical data suggest that drug mono-therapy for MEN2 and other cancers typically yield only moderate benefits as patients develop drug resistance and suffer from drug-induced pathway feedback. Combinations of drugs that target different nodes of the oncogenic pathway are an effective way to prevent resistance as well as feedback. Identifying the optimal drug-dose combinations for therapy poses a significant challenge in existing mouse models. Fly models offer a means to quickly and effectively identify drug combinations that are well tolerated and potently suppress the MEN2 phenotype. This approach may also identify differences in therapeutic responses between the two subtypes of MEN2--MEN2A and MEN2B--providing additional therapeutic insights.
Conclusions:
Fly models have proven useful for identifying known drugs as well as novel compounds that, as single agents or in combinations, effectively suppress the MEN2 syndrome. These findings validate the use of fly models for both drug discovery as well as identification of useful drug combinations. In the future, rapid pairing of new genomic information with increasingly complex fly models will aid us in efforts to further tailor drug treatments toward personalized medicine.
Insights
Fruit fly models effectively identify drug combinations for treating Multiple Endocrine Neoplasia type II (MEN2) cancer. This approach accelerates drug discovery and combination therapy development, offering new insights for personalized medicine.
Area of Science:
- Oncology
- Genetics
- Pharmacology
Background:
- Multiple Endocrine Neoplasia type II (MEN2) is an aggressive cancer lacking effective treatments.
- A novel Drosophila melanogaster model was developed to study oncogenic RET and identify therapeutic compounds.
- ZD6474 (Vandetanib) demonstrated efficacy in suppressing MEN2 tumorigenesis in the fly model.
Purpose of the Study:
- To identify novel genetic modifiers of oncogenic RET.
- To establish a whole-animal system for rapid compound screening against MEN2.
- To explore the utility of fly models for drug discovery and combination therapy development.
Main Methods:
- Development of a Drosophila melanogaster model for MEN2.
- Screening of compounds, including ZD6474 (Vandetanib), for anti-tumorigenic effects.
- Evaluation of drug combinations for efficacy and tolerability in the fly model.
Main Results:
- The Drosophila model successfully identified ZD6474 (Vandetanib) as a suppressor of MEN2 tumorigenesis.
- Fly models proved effective in identifying both single agents and drug combinations against MEN2.
- The study validated the use of fly models for drug discovery and combination therapy optimization.
Conclusions:
- Drosophila models offer a rapid and effective platform for identifying therapeutic drug combinations for MEN2.
- This approach can overcome drug resistance and pathway feedback associated with mono-therapy.
- Future integration with genomic data will advance personalized medicine for MEN2 and other cancers.
